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99mTc-glutathione (99mTc-GSH) is a radiopharmaceutical which is potentially used 
as a cancer diagnostic kit. As with other radiopharmaceuticals, before applied in 
humans, including in clinical trials, 99mTc-GSH needs to go through a series of 
preclinical trials in animal first. The preclinical trial which has been done in this 
study is the evaluation of the biological test on biodistribution and imaging of white 
rats (Rattus norvegicus) which had been induced with cancer. The aims of this 
research were to obtain data on biodistribution and to image the biodistribution of 
99mTc-GSH at 1 hour, 3 hours, and 24 hours post-injection. Biodistribution results 
of 99mTc-GSH in the cancer at the times of 1 hour, 3 hours, and 24 hours after 
injection were 0.66% ID/g, 0.95% ID/g, and 0.06% ID/g, respectively. This result 
shows that the highest accumulation of 99mTc-GSH in cancer occur at 3 hours post-
injection. This value indicates that the optimal accumulation of the 99mTc-GSH 
occur in this time interval. In addition, the results of imaging test also show that the 
accumulation capacity of 99mTc-GSH in cancer is also highest at 3 hours post-
injection. 
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INTRODUCTION 
 
Cancer is defined as a group of diseases 
characterized by uncontrolled growth and spread of 
abnormal cells. In the body, the cancer cells will 
spread to other body parts. This process can cause 
damages to the physiological function, including 
death [1]. Genetically, there are three categories of 
genes which play an important role in regulating the 
growth of cancer cells. The first category includes 
proto-oncogenes which regulate the life cycle of 
cell, cell enlargement, DNA replication, cell 
division, and transfer of sets of genes to daughter 
cells. The second category is genes which restrict 
growth of cancer cell or also called cancer 
suppressor genes. The last category is genes which 
regulates replication and repair of DNA. Most 
cancers come from a mutation in one or more 
categories of genes [2]. 
Cancer is one of the deadly diseases which 
have killed millions of people in the world. Based 
on data from Health Research Association (2007), in 
Indonesia, cancer reached 10.2% of the proportion 
of the total incidences of non-contagious diseases 
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and became the seventh-leading cause of death from 
diseases [3]. In 2007 UICC (Union Internationale 
Contre le Cancer) reported that 8 million people 
worldwide died of cancer; this number comprises 
about 13% of the total deaths from diseases. 
Furthermore, this number was predicted to increase 
to 11.8 million deaths in 2030 [4]. The high 
mortality number is caused by the late cancer 
diagnoses where the incidence is usually discovered 
when the cancer has reached an advanced stage or 
when it displays clinical symptoms in patients. 
Therefore, early diagnoses are needed to reduce the 
mortality due to cancer. 
Presently, nuclear-based imaging techniques 
using radiopharmaceuticals has proven its 
performance in cancer diagnosis. The advantages of 
diagnosis method using radiopharmaceuticals over 
conventional diagnosis method are: higher 
sensitivity and specificity; pain-free operation; and 
speed [5]. In this study, one of the potential 
radiopharmaceuticals for in cancer diagnosis, 
namely 
99m
Tc-glutathione (
99m
Tc-GSH), is studied. 
The 
99m
Tc-GSH radiopharmaceutical is           
a nuclear medical material consisting of    
glutathione compounds labeled with the technetium-
99m radioisotope. 
99m
Tc-GSH has been successfully 
synthesized by the Labelled Compound and 
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Radiometry Division, Nuclear Technology                
Center for Materials and Radiometry-BATAN.                
The compound is expected to be used in nuclear 
medicine as a diagnostic kit for early detection        
of cancer. Early detections of cancer incidence      
are needed to determine the presence of cancer       
in the body in an early stage. This is very     
important because the therapy process is easier in 
the early stages of cancer than in the advanced 
stages. 
Any radiopharmaceutical used for cancer 
diagnosis, including 
99m
Tc-GSH, should optimally 
accumulate in target organ, namely the cancer, so 
the imaging process can be applied to obtain the 
visual data of cancer. In addition, 
99m
Tc-GSH must 
also be non-toxic, non-pyrogenic, and not harmful 
to the body. Therefore, to ensure fulfillment of the 
above requirements, before it can be applied as        
a diagnostic kit, 
99m
Tc-GSH must pass biological 
evaluation stages (preclinical trials) first. 
One of the preclinical trials is the 
biodistribution test. This test aims to determine the 
distribution of the 
99m
Tc-GSH in several vital organs 
when injected into the body. It is very important in 
biodistribution test to observe the accumulation of 
99m
Tc-GSH in target organs, especially the cancer. 
The value of 
99m
Tc-GSH accumulation in                    
target organs is important for the success of                   
the diagnostics. The accumulation of a 
radiopharmaceutical should also be visualized in the 
process of imaging. Therefore, the purpose of this 
study is to determine the biodistribution and 
imaging 
99m
Tc-GSH in the body of white rats 
(Rattus norvegicus) induced with cancer.              
The results from this study are expected                   
to provide recommendations to the clinical trials     
in the field of nuclear medicine for cancer   
diagnosis. 
 
 
EXPERIMENTAL METHODS 
 
Materials and equipment 
 
The materials used in this study were      
99m
Tc-GSH radiopharmaceutical, DMBA (7.12 
dimethyl benz(a)antracene) produced by Aldrich, 
70% alcohol, corn oil, parchment paper, and white 
rats (Rattus norvegicus) of Sprague Dawley (SD) 
strain, aged 4 weeks. Equipment used were               
animal scanner (from Berthoid), feeding stick,                   
Pb containers, conical tubes, single channel analyzer 
(SCA) (Schlumberger), syringe, vortex (Retsch), 
analytical scale (Mettler), dose calibrator, and 
dissecting instruments. 
Carcinogen preparation 
 
Carcinogen preparation was done by 
dissolving the DMBA carcinogen powder to the 
corn oil solution according to the required volume. 
The solution was stirred for 15 minutes until it 
became homogeneous. 
 
 
Cancer induction in white rats 
 
Induction of cancer was performed in female 
rats with DMBA. The DMBA was administered 
twice a week for 8 weeks at the dose of 20 mg/kg 
body weight. DMBA was given orally in a volume 
(ml) which was calculated to fit the mouth to the 
esophagus. Further, the rats which had been induced 
with cancer were maintained for 4-6 months. The 
DMBA dose calculation followed the following 
equation [6]. 
 
  
mg/ml 4
rat oft body weigh x 0.02mg/g
  VolumeDMBA   (1) 
 
 
Cancer nodule palpation  
 
Palpation of cancer nodules in rats which had 
been administered with DMBA was conducted to 
detect cancerous tissue growth. Palpation was 
performed in all rats 1-2 times a week for 4-6 
months. The palpation was carried out by pushing or 
feeling the entire body of the rats, and if any 
nodules (cancer) were found, the rats will be 
recorded as rats with cancer. 
 
 
Biodistribution test 
 
Biodistribution test in rats induced with 
cancer was carried out by injecting 200 μCi of  
99m
Tc-GSH via the tail vein (intravenous). The 
observation was conducted at 1 hour, 3 hours, and 
24 hours after injection by dissecting the rats. The 
cancerous lumps, muscles, hearst, small intestines, 
livers, spleens, kidneys, lungs, stomaches, and blood 
tissues were collected. All organs were weighed, 
then counted with SCA to obtain the accumulation 
of counts per gram organ. Counted values were 
processed to obtain the organ’s percentage injected 
dose per gram of tissue weight (% ID/g), using the 
following formula, to obtain the accumulation 
capacity in each organ [7]. 
 
100%x 
given dose counts
organ   gramper  counts  
   ID/g %   (2) 
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Imaging test  
 
Imaging tests were done on rats induced with 
cancer. Rats were intravenously injected with the 
99m
Tc-GSH via the tail vein at dose of 2 mCi.        
The imaging process was performed at 1 hour,                   
3 hours, and 24 hours post-injection, on different 
rats, using an animal scanner. 
 
 
Data analysis 
 
All parameters in this study were observed              
as triples. The data were analyzed using                    
a quantitative ANOVA (Analysis of Variance) and 
DMRT (Duncan Multiple Range Test). Significance 
level used is 5% to determine whether there is any 
difference in accumulation capacity of the rat 
organs, while the qualitative data were analyzed by 
descriptive statistics. 
 
 
RESULTS AND DISCUSSION 
 
The 
99m
Tc-GSH radiopharmaceutical injected 
via the tail vein was distributed through the body by 
the bloodstream. The distribution, accumulation, 
and ellimination of a radiopharmaceutical is highly 
dependent on the entry path, the chemical form, and 
metabolism in the body. The accumulation value 
(expressed in % ID/g) of the organ is important in 
determining the success of the diagnosis method. 
The accumulated value can also be used to consider 
the safety of a radiopharmaceutical for the body. 
On the physico-chemical properties, the 
99m
Tc-GSH used has a radiochemical purity of 99.54 
± 0.01% and is stable for up to 5 hours at room 
temperature and at 4
o
C. Those properties are 
important for the success of the diagnosis process. 
The high radiochemical purity of the 
99m
Tc-GSH 
means that there was less impurities in stocks. 
Hence it made the 
99m
Tc-GSH relatively                     
stable, especially from its chemical bonds so that  
the accuracy of the data collection can be 
recognized [8]. 
The 
99m
Tc-GSH application in this study was 
carried out by injection through the tail vein. This 
was aimed at accelerating the distribution of the 
radiopharmaceutical to the organs as it flows with 
the blood. It also has the benefit of reducing the 
residence time of the radiopharmaceutical in the 
body but still within the optimal duration for the 
diagnosis. Some studies have been conducted 
regarding the radiopharmaceutical biodistribution 
via tail vein injection process. Sumpena (2008) and 
Sugiharti (2009) examined the biodistribution of 
99m
Tc-CTMP [9] and 
99m
Tc-Human Serum Albumin 
[10], respectively. The biodistribution of 
99m
Tc-GSH 
is shown in Fig. 1. 
 
 
 
Fig. 1. Biodistribution of 99mTc-GSH in rats with cancer at 1 hour,          
3 hours, and 24 hours post injection. 
 
Biodistribution results (Fig. 1) show that the 
average value of % ID/g was different for different 
organ and different time intervals. In muscle organ 
the average % ID/g of 
99m
Tc-GSH at 1 hour, 3 hours, 
and 24 hours after injection were 0.10, 0.08, and 
0.01% ID /g respectively. There was a decrease of 
99m
Tc-GSH in muscle organ during the time interval 
to 24 hours. 
The decrease in accumulation value over time 
also happened to almost all other organs. The 
accumulation value for each organ after from 1 
hour, 3 hours, and 24 hours were as follows: in the 
blood (1.12, 0.85, and 0.03% ID/g respectively), 
stomach (0.26, 0.22, and 0.01% ID/g), small 
intestine (0.38, 0.29, and 0.02% ID/g), spleen (0.13, 
0.13, and 0.05% ID/g), kidney (18.61, 16.68, and 
7.19% ID/g), heart (0.24, 0.17%, and 0.01% ID/g), 
and lung (0.27, 0.25, and 0.04% ID/g). An exception 
was the liver, for which there was a slight increase 
in the accumulation of the 
99m
Tc-GSH at 3 hours 
post-injection in the amount of 0.02% ID/g. 
The increased 
99m
Tc-GSH accumulation in the 
liver may be caused by the wider availability of 
glutathione compounds in the liver compared to the 
other organs [11]. However, this increase is 
relatively small, so its impact is not significant, and 
at 24 hours, the 
99m
Tc-GSH accumulation has 
decreased as in other organs. Sumpena (2010) also 
reported a decline of 
99m
Tc-GSH accumulation over 
time in most organs in normal mice [12]. 
Overall, all organs showed decreasing 
99m
Tc-
GSH accumulation over time, and accumulation 
values in those organs show no significant 
difference except for the blood, kidneys, and cancer. 
Accumulation in the stomach indicates a Tc-
complex decomposition in biodistribution test [13]. 
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The decomposition of Tc-complex is closely related 
to the physiological function of the stomach for 
digesting food. In hepatobiliary organs (small 
intestine, spleen, and liver) the accumulation of the 
99m
Tc-glutathione was relatively low (<0.5% ID/g). 
This value showed that the uptake of these organs 
was low so 
99m
Tc-GSH is safe for use. 
The decrease in the accumulation of 
99m
Tc-
GSH in all organs over time indicates that the 
clearance by each organs had occurred [14]. This is 
supported by the high value of % ID/g in the 
kidneys compared to in the other organs (Fig. 1). 
This situation is in line with one of the functions of 
kidneys, namely accommodating wastes from all 
cellular metabolism and excreting them through 
urine. The metabolic wastes are brought by the 
blood flow through kidney glomerulus where those 
wastes are filtered [15]. The clearance of the 
99m
Tc-
GSH from blood follows the same pattern with the 
clearance by the kidneys. From these results it can 
be said that the clearance of the 
99m
Tc-GSH from the 
body went well because it did not accumulate in any 
tissue for too long; thus, it can be said that this result 
indicates that 
99m
Tc-GSH is safe for the body. 
Long term accumulation of a 
radiopharmaceutical in specific organs is very 
dangerous and should be avoided, as the emitted 
radiation of the radiopharmaceutical can damage 
organs. The damage potentially include various 
mutations and chromosome aberrations [16]. 
Cancer tissues, which are the main purpose of 
the diagnosis, accumulated 
99m
Tc-GSH to relatively 
higher concentrations compared to other organs 
except blood and kidneys at 1 hour, 3 hours, and 24 
hours with values of 0.66% ID/g, 0, 95% ID/g, and 
0.06% ID/g, respectively. The high value of 
accumulation in the cancer is related to the function 
of the glutathione compound in the body. Naturally, 
a certain level of glutathione can be produced by 
body cells. However, infections or inflammations in 
an organ will increase glutathione levels because of 
the function of glutathione in the formation of 
antibodies in fighting infection or inflammation 
[17]. Therefore, 
99m
Tc-GSH in the blood will go to 
the cancer as a target organ (abnormal organ). When 
reaching the cancer, 
99m
Tc-GSH will be uptaken and 
then accumulated in those organs. 
The data also shows that the highest 
accumulation value of 
99m
Tc-GSH occurred at 3 
hours post-injection. It can be concluded that the 
optimal accumulation of 
99m
Tc-GSH for cancer 
diagnosis occurs at 3 hours post-injection. 
A previous study conducted by Ralna (2010) 
on the 
125
I-Nimotuzumab radiopharmaceutical for 
brain cancer therapy found that the highest 
accumulation occurs 24 hours post-injection at 
0.13% ID/g. This value is still low compared with 
the accumulation of 
99m
Tc-GSH at 3 hours post-
injection which is 0.95% ID/g [18]. 
The high accumulation of the 
99m
Tc-GSH in 
cancer at 3 hours post-injection is also supported by 
the ratio of cancer and blood accumulation.                 
The ratios of % ID/g between cancer and blood at              
1 hour, 3 hours, and 24 hours are 0.6, 7.4, and 2.0, 
respectively (Fig. 2). From these data it is observed 
that the highest ratio occurs at the 3 hours post-
injection 
99m
Tc-GSH. 
 
 
Fig. 2. The ratio of % ID/g between cancer and blood. 
 
The cancer-% ID/g-to-blood-% ID/g ratio was 
highest at 3 hours post-injection. It indicated that the 
99m
Tc-GSH was uptaken very well by the cancer at 
this time. The result also agrees with the value of 
the accumulation of 
99m
Tc-GSH at 3 hours post-
injection from the biodistribution test. The ratio may 
also indicate that at 3 hours post injection 
99m
Tc-
GSH has undergone the process of clearance by the 
blood. The higher ratio of radiopharmaceutical 
which is distributed to target organ to which is 
distributed to other organs will generate better 
images and facilitate more accurate diagnoses of the 
disease [19]. 
At the 24 hours post-injection the ratio of 
blood and cancer significantly decreased. It 
indicates that the uptake capacity of 
99m
Tc-GSH by 
cancer has declined. ANOVA and DMRT statistical 
analysis show that the accumulation value of the 
99m
Tc-GSH in rat organs show no significant 
difference from each other, except for the kidneys. 
This situation occured because accumulation values 
in the kidneys are much different from accumulation 
values in other organs. In the kidneys, accumulation 
values were significantly different (α = 0.05) from 
accumulations in other organs.
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(a) (b) (c) 
 
Fig. 3. Imaging of 99mTc-GSH in rats with cancer at 1 hour (a), 3 hours (b), and 24 hours (c) post injection. 
 
Imaging test results indicate that the 
accumulations of 
99m
Tc-GSH in cancer at 1 hour,      
3 hours, and 24 hours post-injection are different. 
Figure 3 shows that the highest accumulation of 
99m
Tc-GSH occur at 3 hours post-injection. This can 
be seen from the results of imaging test in which the 
color of cancer was darkest at 3 hours post-
injection. 
These imaging test results are in accordance 
with the biodistribution test results in which          
the highest accumulation of 
99m
Tc-GSH occurred at       
3 hours post-injection. At 1 hour post-injection    
(Fig. 3a) cancer color is not as dark as at 3 hours 
post-injection (Fig. 3b). This is probably because 
the 
99m
Tc-GSH is still experiencing biodistibution   
in blood, or it may also mean that 
99m
Tc-GSH        
has just started to enter the cancer organ. Further, at 
24 hours post-injection (Fig. 3c), the image has 
become less dark than at 3 hours. This may be 
caused by two factors. First, the 
99m
Tc-GSH 
accumulating in the cancer may have undergone  a 
clearance. Second, it may also be caused by the 
decay of technetium-99m bound to glutathione 
group. Technetium-99m has a half-life of 6 hours 
[20], which means that every 6 hours the 
radioactivity of this compound halves. As a                 
result, 24 hours after injection, the 
99m
Tc-GSH   
radioactivity measured during imaging has 
decreased by over 90%. 
The basic principle of imaging test is 
detection and quantification of the activity of           
a radiopharmaceutical followed by visual display of 
the results. In the resulting image, accumulation of 
the radiopharmaceutical can be observed from                    
the indicated level of darkness of a particular              
organ. Darker parts indicate radiopharmaceutical 
accumulation as measured by the animal scanner.    
In this case, the presence of accumulation of dark 
part in a particular organ may signify that there is     
a growing cancer. 
The higher the accumulation level of a 
radiopharmaceutical in an organ, the easier it 
becomes to create images of the organ with an 
animal scanner or a gamma camera [21]. However, 
this principle is difficult to apply to observing 
kidneys as they are basically always accumulating 
higher quantities of radiopharmaceutical than other 
organs. This is caused by the function of kidneys as 
excretory organs. Therefore, diagnosis of kidney 
cancer is usually conducted with a different, special 
method. 
 
 
CONCLUSION 
 
Based on the test results it can be concluded 
that 
99m
Tc-GSH effectively reaches the target              
organ (cancer) at 3 hours post-injection with a 
concentration of 0.95% ID/g. This data agrees with 
the imaging test results which also showed the 
highest accumulation of 
99m
Tc-GSH at 3 hours post-
injection. In addition, 
99m
Tc-GSH also showed high 
values of renal and blood clearance which indicates 
that it is relatively safe for the body. From these 
results, it can be concluded that 
99m
Tc-GSH is ready 
to proceed to clinical trials. 
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